La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Chord Energy a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Chord Energy..

Chord Energy (OTC:WLLBW) Azioni, Catena delle Opzioni

Chord Energy Corp is an independent exploration and production company. The company acquires, exploits, develops, and explores crude oil, natural gas, and natural gas liquids in the Williston Basin.

Elon Musk's SpaceX is gearing up for a jaw-dropping $400 billion valuation in its <a href="https://www.benzinga.com/news/space/25/07/46312510/elon-musks-spacex-insider-share-sale-could-push-valuation-to-400-billion-starlink-is-the-rocket-fuel">latest insider share sale</a>. But if you're not an employee, investor, or close friend of the rocket maker, you're probably stuck on the sidelines. 
SpaceX's tender offer allows employees and early investors to cash out their shares at soaring prices, but public access remains tightly locked down. This latest $400 billion valuation is a reminder of how out of reach these mega-privates have been.
Read Also: <a href="https://www.benzinga.com/news/politics/25/07/46307371/musk-vs-trump-tesla-ceo-is-down-87-billion-in-2025-but-still-worth-49x-more-than-trump-media-trump-coin">Musk Vs. Trump: Tesla CEO Is Down $87 Billion In 2025 But Still Worth 49X More Than Trump Media &amp; Trump Coin</a>
<h2 class="wp-block-heading">OpenAI, SpaceX, Epic — Now in Your Pocket</h2>
Enter SoFi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) &#8211; quietly giving retail investors a rare shot at owning pieces of SpaceX, OpenAI, Epic Games, and other private giants, starting with just 10 bucks.
SoFi's <a href="https://investors.sofi.com/news/news-details/2025/SoFi-Expands-Access-to-Private-Markets-with-Funds-from-Cashmere-Fundrise-and-Liberty-Street-Advisors/default.aspx">new funds</a>, backed by Cashmere, Fundrise, and Liberty Street Advisors, bundle private market opportunities into accessible portfolios inside the SoFi app. Retail investors can enter with a minimum investment as low as $10, gaining exposure to high-growth companies previously reserved for Silicon Valley insiders and large funds.
<h2 class="wp-block-heading">The Democratization Of Billion-Dollar Bets</h2>
With late-stage private valuations skyrocketing and IPOs staying frozen, these curated funds may be the only way regular investors can snag a slice of tomorrow's tech titans today. 
It's a democratization of access, making previously rarefied opportunities practical for anyone with a smartphone and a few bucks to spare.
<h2 class="wp-block-heading">Why It Matters</h2>
While SpaceX's $400 billion valuation dominates headlines, the real story might be SoFi quietly rewriting the rules of private market investing.
For investors eager to ride the next wave of innovation without the billionaire-only price tag, the door just cracked wide open.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46186180/raoul-pal-says-robinhood-letting-users-trade-openai-spacex-through-blockchain-is-democratization-of-finance-end-of-public-vs-private-markets-has-begun">Raoul Pal Says Robinhood Letting Users Trade OpenAI, SpaceX Through Blockchain Is &#8216;Democratization Of Finance&#8217; — End Of Public Vs Private Markets Has Begun</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Long Ideas

Tech

Trading Ideas

SOFI

Can't Buy SpaceX Stock? SoFi Just Opened The Backdoor — And It Starts At $10

Dave Ramsey, a renowned personal finance expert, has shared his views on the prioritization of 401(k) plans over college funds. He believes that saving for retirement should take precedence over saving for a child&#8217;s college education.
What Happened: Ramsey, in an email to TheStreet, emphasized the importance of prioritizing retirement savings over college funds. He stated that while saving for a child&#8217;s college education is a noble endeavor, it should not take precedence over retirement savings, <a href="https://www.thestreet.com/retirement/dave-ramsey-sends-strong-message-to-americans-on-401-k-plans?ref=biztoc.com">reported</a> TheStreet.
&#8220;Setting&nbsp;aside a college fund for&nbsp;your kids is a really&nbsp;nice thing to do, if&nbsp;you can actually afford that&nbsp;kind of thing,&#8221; Ramsey wrote. &#8220;But&nbsp;kids can also further their&nbsp;education by getting good grades,&nbsp;applying for scholarships, choosing a&nbsp;school they can afford and&nbsp;working their tails off while&nbsp;attending classes.&#8221;
Ramsey also emphasized the various ways to obtain a college degree without relying on parents&#8217; savings. He then stressed the necessity of retirement savings, stating that everyone will eventually retire, unless they pass away before reaching retirement age.
He also stressed the need for early financial preparation for retirement. Ramsey advocates for saving as much as possible to ensure a comfortable life during the golden years.
Ramsey addressed the financial constraints some parents face, stating that not being able to contribute to a child&#8217;s education &#8220;doesn't make them bad parents.&#8221; Ramsey is a strong advocate for Roth IRAs as a preferred investment vehicle, citing their flexibility and long-term benefits.
SEE ALSO: <a href="https://benzinga.com/news/politics/25/07/46312553/trump-thanks-ron-desantis-florida-lawmakers-for-renaming-4-mile-stretch-near-mar-a-lago-donald-j-tr" target="_blank" rel="noreferrer noopener">Trump Thanks Ron DeSantis, Florida Lawmakers for Renaming 4-Mile Stretch Near Mar-a-Lago &#8216;Donald J. Trump Boulevard,&#8217; Calls It a &#8216;Wonderful Honor&#8217;</a>
Why It Matters: Ramsey&#8217;s views on retirement savings and college funds are consistent with his previous statements on financial planning. In a recent article, Ramsey encouraged parents to set realistic boundaries for their children&#8217;s college education. He advised against taking out <a href="https://www.benzinga.com/personal-finance/management/25/07/46279015/dave-ramsey-encourages-parents-to-get-honest-about-what-they-can-afford-for-their-chi">student loans</a> if parents cannot afford their children&#8217;s tuition.
Earlier this year, Ramsey also criticized workers who abandoned their<a href="https://www.benzinga.com/personal-finance/financial-advisors/25/05/45187836/dave-ramsey-blasts-budget-slackers-who-bail-on-401ks-during-market-turmoil-shortterm-temper-tantrums"> 401(k) plans</a> during market turmoil. He stressed the importance of a disciplined financial approach and the need to prioritize retirement savings.
However, Ramsey&#8217;s advice has not always been well-received. In a separate incident, he advised a 28-year-old caller against draining her 401(k) and IRA for a <a href="https://www.benzinga.com/personal-finance/25/05/45424768/28-year-old-refuses-to-sell-crypto-but-wants-to-drain-her-401k-and-ira-for-a-750k-house-dave-ramsey-tells-her-youre-too-broke">house purchase</a>. His advice was met with criticism from some who felt it did not consider the caller&#8217;s individual circumstances.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/personal-finance/management/25/07/46263095/my-bodys-getting-achier-every-day-disabled-veteran-with-7500-monthly-income-and-no-savings-should-he-retire-or-wait-3-more-years">&#8216;My Body&#8217;s Getting Achier Every Day&#8217;: Disabled Veteran With $7,500 Monthly Income And No Savings — Should He Retire Or Wait 3 More Years?</a> </li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

News

Dave Ramsey Warns Americans Against Prioritizing Kids' College Funds Over 401(k)s — Says It Doesn't Make You 'Bad Parents'

Morgan Stanley analyst Joshua Pokrzywinski maintains Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) with a Equal-Weight and raises the price target from $700 to $725.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Parker Hannifin, Raises Price Target to $725

Sernova Biotherapeutics ("Sernova") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SVA#TSX">SVA</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/SEOVF#OTCQB">SEOVF</a>) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) to evaluate Eledon's immunosuppressive agent tegoprubart (AT-1501) in Sernova's ongoing Phase 1/2 clinical trial of its Cell Pouch Bio-hybrid Organ in patients with type 1 diabetes (T1D).
Under the terms of the agreement, Eledon will supply tegoprubart, an investigational anti-CD40L antibody being evaluated for its potential to prevent transplant rejection in islet cell, kidney and xeno transplantation, will be used in place of tacrolimus in the upcoming Cohort C of Sernova's Phase 1/2 clinical trial. Tacrolimus is currently a standard immunosuppressive drug used in organ transplantation to prevent rejection. However, its potential toxicity, particularly toward insulin-producing beta cells, and its side effect profile limit its suitability as an optimal immunosuppressive agent for islet cell therapy in T1D.
In an investigator-initiated study led by Dr. Piotr Witkowski, a leading expert in islet transplantation at the University of Chicago, T1D patients received islet transplants along with tegoprubart to prevent rejection. Three participants achieved normal, stable blood sugar levels and became insulin independent. Islet engraftment, measured by graft function standardized to the number of islets infused, was three to five times higher than in comparable subjects outside this study who received tacrolimus-based immunosuppression, suggesting treatment with tegoprubart better protects transplanted islets resulting in improved graft survival and function. Treatment was generally well tolerated in all subjects with no unexpected adverse events or severe hypoglycemic episodes.

Biotech

General

ELDN

SEOVF

TSX:SVA

Eledon And Sernova Collaborate To Test Tegoprubart As Safer Immunosuppressant In Sernova's Phase 1/2 Cell Pouch Trial For Type 1 Diabetes

HSDT

Helius Receives Nasdaq Compliance Notice For Continued Listing On Nasdaq Capital Market

Guidance

ONDS

Ondas Expects To Report ~$6M In Revenue For Quarter Ended Jun. 30

ERNA

Ernexa Therapeutics Regains Nasdaq Compliance

FBLG

FibroBiologics Confirms That CYWC628 Spheroids Used In Wound Healing Program Can Be Directly Differentiated Into Chondrocytes

<ul>
<li>Award includes significant renewal and expansion in Midwest with long-standing combination utility customer</li>
<li>Project award supports sustainable infrastructure development in the Northeast</li>
</ul>
Centuri Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) ("Centuri" or the "Company"), a leading, North American utility infrastructure services company, today announced more than $550 million in new customer awards. These awards further showcase the Company's ability to capitalize on opportunities within its current customer base while simultaneously supporting the infrastructure essential to building next-generation energy solutions.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20250709349697/en/">https://www.businesswire.com/news/home/20250709349697/en/</a>
Centuri is expanding its presence in key markets building both natural gas and electric infrastructure for its utility customers.
The revenue value of the announced awards largely reflects a significant multi-year contract renewal for one of the largest regulated combination utilities in the United States with strategic expansion into adjacent territories. The total also includes a contract to build a Renewable Natural Gas facility in the Northeast, the fourth of its kind for Centuri's union electric division, where the Company will serve as lead project delivery contractor. Today's release comes on the heels of $575 million in awards <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.centuri.com%2Fnews%2Fnews-details%2F2025%2FCenturi-Announces-Over-575-Million-in-Customer-Awards-Across-the-U-S-%2Fdefault.aspx&amp;esheet=54287078&amp;newsitemid=20250709349697&amp;lan=en-US&amp;anchor=announced&amp;index=1&amp;md5=2a990ae36d6fe52d50f84587c3059f1f">announced</a> on June 23, 2025.

Contracts

CTRI

Centuri Holdings Secures Over $550M In New Multi-Year Utility Infrastructure Contracts Including Midwest Expansion And Northeast Renewable Natural Gas Project, Following $575M Awards In June

CLOV

Clover Health Investments Launches Community-Based Pharmacy Pilot Program Across New Jersey.

Early positive consumer testimonials from initial Company product sampling
Sublingual nano technology delivers caffeine rapidly to the bloodstream, bringing its unique benefits to the pre-workout market
Developed through over a decade of scientific research to deliver a patent-pending, fast-acting supplement formulation for maximum effect
Completed initial production in four flavors
Aspire to launch BUZZ BOMB&#x2122; at the FITCON and Fit Expo conventions in August
ESTERO, FL AND NEW YORK, NY / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 9, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced positive initial consumer feedback from the Company's sampling of its sublingual pre-workout supplement, BUZZ BOMB&#x2122;. Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB&#x2122; is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout market to help athletes and fitness enthusiasts maximize their performance potential. Buzz Bomb&#x2122; provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed.
Last month, BUZZ BOMB&#x2122; began a soft launch of its product line, introducing it to strength trainers, consultants, and fitness professionals. Aspire sees BUZZ BOMB&#x2122; as more than just another supplement; it is a science-driven brand focused on understanding nutrition, performance, and the daily needs of athletes and fitness enthusiasts. BUZZ BOMB&#x2122; is a pre-workout solution that boosts endurance, energy metabolism, and overall performance, primarily through caffeine, a well-researched ingredient shown to enhance fitness results. Unlike pre-workout products that are mixed with water and taken well before a workout, BUZZ BOMB is sprinkled under the tongue for immediate effect.

ASBP

Aspire Biopharma's BUZZ BOMB Receives Early Reviews For Fast-Acting Sublingual Pre-Workout Supplement Ahead Of August FITCON Launch

When copper prices exploded by more than 13%—marking the <a href="https://www.benzinga.com/markets/equities/25/07/46305321/copper-price-surges-trump-tariffs-stocks-july-2025">biggest single-day gain in history</a>—in response to President Donald Trump&#8216;s latest tariff threat, commodity investors cheered.
But for Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), that chart may as well have been a warning flare. With every Model Y and Cybertruck packing over 180 pounds of copper, the metal's meteoric rise just made building an EV a whole lot pricier.
<h2 class="wp-block-heading">Tesla's Copper Habit Just Got Expensive</h2>
Electric vehicles are copper gluttons. From motors to wiring to battery connectors, the red metal is the unsung hero of electrification. While a traditional gas-powered car uses around 50 pounds of copper, Teslas use more than three times that amount—roughly <a href="https://www.mining.com/new-tesla-low-voltage-system-a-big-deal-for-copper-says-musk/" target="_blank" rel="noreferrer noopener">180 pounds</a> per vehicle.
That makes Elon Musk's production lines especially vulnerable to copper's mood swings. And right now, copper is throwing a tantrum.
Read Also: <a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/07/46308347/trumps-big-beautiful-bill-too-much-for-tesla-stock-direct-hit-to-profitability">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Too Much For Tesla Stock: &#8216;Direct Hit To Profitability&#8217;</a>
<h2 class="wp-block-heading">Blame The Tariff—Or The Speculators?</h2>
Jim Cramer thinks the surge isn't entirely organic. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The copper tariff is gratuitous. It makes data centers more costly. Of course, it makes a Tesla more expensive to make as it has a huge amount of copper in it. Please let that NOT be the reason for this tariff&#8230;
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1942750426417238077?ref_src=twsrc%5Etfw">July 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He took to X to call the Trump administration's copper tariff "gratuitous," warning it could make both data centers and Teslas more expensive to build. And with AI infrastructure and EVs both guzzling copper like there's no tomorrow, that extra cost has nowhere to hide.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">JUST IN &#x1f6a8;: Copper gets a God Candle as it explodes by more than 13% for its biggest gain IN HISTORY &#x1f4c8;&#x1f4c8; <a href="https://t.co/rnj0KrtsZa">pic.twitter.com/rnj0KrtsZa</a>
&mdash; Barchart (@Barchart) <a href="https://twitter.com/Barchart/status/1942695893230137579?ref_src=twsrc%5Etfw">July 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, traders are calling the surge a "God Candle"—a slang term for an epic breakout, noted Barcharts on X. Whether the move sticks or fizzles, companies like Tesla will feel it first.
<h2 class="wp-block-heading">A Shock To The Supply Chain</h2>
The irony? 
Copper was supposed to be the backbone of the green transition. Now it's threatening the affordability of EVs just as mainstream adoption gains speed. 
Tesla, which has long prided itself on vertical integration and margin control, may soon be forced to make some tough sourcing decisions.
For now, investors might enjoy the heat in copper miners. But Tesla? It's sweating the small stuff—180 pounds of it per car.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46307371/musk-vs-trump-tesla-ceo-is-down-87-billion-in-2025-but-still-worth-49x-more-than-trump-media-trump-coin">Musk Vs. Trump: Tesla CEO Is Down $87 Billion In 2025 But Still Worth 49X More Than Trump Media &amp; Trump Coin</a></li>
</ul>
Photo: Shutterstock

Technicals

Commodities

Markets

TSLA

Tesla Is Getting Burnt By Copper's God Candle

CELU

Celularity Enters Partnership With Fountain Life To Supply Stem Cell Therapy Products

WIIM

VRCA

Verrica Pharmaceuticals shares are trading higher after the company reported record growth for its YCANTH applicator.

The study revealed significant dose-dependent inhibition in lung cancer cells harboring KRAS G12D mutations, with notable efficacy, highlighting SIL204's potential as a versatile therapeutic for lung cancer. The results also support Silexion's lipid-conjugated delivery system for enhancing SIL204 drug entrance into tumor cells; overcoming a known barrier for siRNA technology and one which is critical for therapeutic efficacy in solid tumors.
 &nbsp;

SLXN

Silexion Therapeutics Announces Preclinical Data Demonstrating SIL204 Efficacy In Human Lung Cancer Cell Lines

Vertical Aerospace Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) on Tuesday announced a public offering to raise $60 million through the sale of ordinary shares, sending its stock lower as investors reacted to dilution concerns and financial uncertainty.
Proceeds from the raise will fund continued aircraft development, including testing, certification, and general corporate needs.
The offering comes after the company&#8217;s May reveal of a hybrid-electric variant of its VX4 aircraft, which integrates both electric and conventional propulsion systems for wider operational use.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45911485/vertical-aerospace-stock-bristow-evtol">Vertical Aerospace Takes Off As Bristow Doubles Down On VX4 Aircraft</a>
Underwriters were also given a 30-day option to purchase up to an additional $9 million in shares, subject to market conditions.
Vertical faces major regulatory hurdles, requiring coordination with the FAA, EASA, and CAA to certify the aircraft. Delays could push back commercial timelines and strain partnerships.
The company also plans to target defense, logistics, and air ambulance markets—applications demanding longer range and greater payload. However, working with government contractors introduces added risk, including complex procurement rules, shifting budgets, and tight compliance requirements. Failures in these areas could jeopardize future deals and limit revenue growth.
As of June 30, 2025, Vertical reported preliminary cash and equivalents of £62 million, a figure still pending auditor review and subject to adjustment.
Investors tracking the broader innovation and aerospace sectors can consider ETFs such as ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) and SPDR S&amp;P Kensho Smart Mobility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAIL#NYSE">HAIL</a>).
EVTL shares have a 52-week range of $2.759 to $15.99. Year-to-date, EVTL is down roughly 45% and is currently trading about 12% below its 50-day simple moving average
Price Action: At the last check on Wednesday, EVTL shares were trading lower by 25% at $5.20 premarket.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46300346/joby-aviation-stock-is-surging-tuesday-whats-going-on">Joby Aviation Stock Is Surging Tuesday: What&#8217;s Going On?</a></li>
</ul>
Photo by Mameraman via Shutterstock

Movers

ALVO

ARKQ

EVTL

GLCR

HAIL

Vertical Aerospace's $60 Million Share Offering Sends Shares Crashing

DFDV

DeFi Development Integrates DoubleZero Into Its Validator Operations As Part Of Infrastructure Experimentation And Innovation In Solana Ecosystem

Stifel analyst Tom Stephan maintains RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) with a Hold and lowers the price target from $17 to $9.

RXST

Stifel Maintains Hold on RxSight, Lowers Price Target to $9

<a href="https://www.globenewswire.com/Tracker?data=7gHBLcDmWRxhnomPhOzdFHIZ-PxD_4u8ueeqzOBY4i7b2otgLGOhj4Eh-GmZxGa_QSAW9iPW8M7NckiOP3dbWzIWl9ULotezdFa6vqGPLKKHCLoz32MMFd_Pn8dwYrlh">Salarius Pharmaceuticals, Inc.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) (Salarius or the Company) announces that two animal studies recently published in peer-reviewed journals provide additional insight into the role of inhibiting lysine-demethylase 1 (LSD1 or KDM1A), a well-validated target in hematologic and solid tumors. Salarius' seclidemstat (SP-2577) is a first-in-class, orally bioavailable LSD1 inhibitor that is being evaluated in an investigator-initiated Phase 1/2 clinical study at MD Anderson Cancer Center (MDACC) as a potential treatment for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) in patients with limited treatment options.

Salarius Pharmaceuticals Announces Two Animal Studies Recently Published In Journals Demonstrating Role Of LSD1

Stifel analyst Steven Wieczynski maintains Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Buy and raises the price target from $310 to $400.

Stifel Maintains Buy on Royal Caribbean Gr, Raises Price Target to $400

Chord Energy Corp Warrants - Series B (01/09/2024)

Comments

Chord Energy

Chord Energy (WLLBW) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO